ArticleCellular and molecular life sciences : CMLS2026
TRPV4 is involved in NLRP3 and NLRP1 inflammasomes activation after pilocarpine-induced status epilepticus in mice : Concise title: TRPV4-mediated inflammasome activation in epilepsy.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain-containing 1 (NLRP1) and NLRP3 inflammasomes are activated in temporal lobe epilepsy (TLE), leading to neuroinflammation, pyroptosis, and neuronal injury. Protein phosphatase 2 A (PP2A) and the toll-like receptor 4 (TLR4)–p38 MAPK signaling pathway participate in regulating these inflammasomes. Although blocking transient receptor potential vanilloid 4 (TRPV4) alleviates inflammation and neuronal damage after pilocarpine-induced status epilepticus (PISE), the underlying mechanisms remain unclear. Here, we found that NLRP1 and NLRP3 expression and activation were markedly increased in the hippocampus during the acute phase post-PISE, accompanied by enhanced pyroptosis and inflammatory responses. Both PP2A activity and TLR4–p38 MAPK signaling were upregulated. Pharmacological inhibition revealed that PP2A primarily drove NLRP3 activation, whereas TLR4–p38 MAPK signaling promoted NLRP1 activation, collectively contributing to pyroptosis and neuronal injury. TRPV4 blockade simultaneously suppressed PP2A activity and TLR4–p38 MAPK signaling, thereby inhibiting NLRP1/NLRP3 inflammasome activation and exerting neuroprotective effects. Conversely, TRPV4 activation with GSK1016790A promoted inflammasome activation, pyroptosis, and activation of PP2A and TLR4–p38 MAPK signaling; these effects were attenuated by inhibiting PP2A or TLR4–p38 MAPK. In HT-22 cells, TRPV4 activation activated the TLR4–p38 MAPK–NLRP1 axis, and NLRP1 knockdown alleviated pyroptosis. Finally, inhibition of TRPV4, PP2A, NLRP3, or NLRP1 markedly reduced seizure frequency and duration in PISE mice. Collectively, these findings suggest that TRPV4 blockade suppresses the PP2A–NLRP3 and TLR4–p38 MAPK–NLRP1 pathways, attenuating neuroinflammation and pyroptosis, and thereby reducing seizure activity during the acute phase following PISE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.